TriLink Biotechnologies Announces Supplier Agreement with Applied Biosystems
News Nov 08, 2007
TriLink Biotechnologies announced that it has signed a service agreement with Applied Biosystems to supply reagents for Applied Biosystems' recently launched next-generation genetic analysis platform, the SOLiD™ System.
As part of the agreement, TriLink is providing Applied Biosystems with custom dye-labeled oligonucleotides, or chemically synthesized nucleotides, which are used as part of the DNA sequencing process.
"Working with best-in-class suppliers like TriLink has enabled us to develop the most robust, accurate, and highest-throughput genetic analysis platform available to help our customers take advantage of the emerging applications for next-generation DNA sequencing," said Kim Caple, vice president and general manager for Applied Biosystems' next-generation sequencing business.
"We are proud that Applied Biosystems has chosen TriLink to be the supplier of the oligonucleotides used in the SOLiD™ system," said TriLink CEO, Dr. Richard Hogrefe.
New Cell-weighing Technique Helps Predict How Drugs Affect Cancer CellsNews
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.READ MORE
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE
Defects in Cell’s ‘Waste Disposal System’ Linked to Parkinson’sNews
An international study has shed new light on the genetic factors associated with Parkinson’s disease, pointing at a group of lysosomal storage disorder genes as potential major contributors to the onset and progression of this common neurodegenerative disorder.READ MORE